MGI(SH:688114) Xin Lang Cai Jing·2026-01-05 01:43Group 1 - The core viewpoint of the news is that BGI Genomics has shown fluctuations in its stock performance and financing activities, indicating a mixed market sentiment towards the company [1][2]. - As of December 31, BGI Genomics' stock price increased by 0.07%, with a trading volume of 96.99 million yuan. The net financing buy was -834,600 yuan, indicating more repayments than new purchases [1]. - The total balance of margin trading for BGI Genomics reached 398 million yuan, with a financing balance of 392 million yuan, accounting for 1.56% of the circulating market value, which is above the 60th percentile of the past year [1]. Group 2 - As of September 30, the number of shareholders for BGI Genomics increased to 15,400, a rise of 14.17%, with an average of 26,794 circulating shares per person, up by 69.94% [2]. - For the period from January to September 2025, BGI Genomics reported an operating income of 1.869 billion yuan, a slight decrease of 0.01% year-on-year, while the net profit attributable to shareholders was -120 million yuan, reflecting a significant increase of 74.20% year-on-year [2]. - Since its A-share listing, BGI Genomics has distributed a total of 150 million yuan in dividends [3].